Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 5
1989 4
1990 5
1991 5
1992 2
1993 2
1994 2
1996 3
1997 5
1998 2
1999 6
2000 5
2001 5
2002 6
2003 6
2004 8
2005 7
2006 9
2007 10
2008 8
2009 9
2010 13
2011 12
2012 18
2013 9
2014 15
2015 17
2016 24
2017 22
2018 25
2019 34
2020 31
2021 32
2022 28
2023 34
2024 30
2025 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

409 results

Results by year

Filters applied: . Clear all
Page 1
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases.
Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, Burazor I, Caforio ALP, Damy T, Eriksson U, Fontana M, Gillmore JD, Gonzalez-Lopez E, Grogan M, Heymans S, Imazio M, Kindermann I, Kristen AV, Maurer MS, Merlini G, Pantazis A, Pankuweit S, Rigopoulos AG, Linhart A. Garcia-Pavia P, et al. Eur Heart J. 2021 Apr 21;42(16):1554-1568. doi: 10.1093/eurheartj/ehab072. Eur Heart J. 2021. PMID: 33825853 Free PMC article.
Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the deposition of amyloid fibrils at the cardiac level. ...Furthermore, we also review how to monitor and treat cardiac amyloidosis, in an attempt to bridge the gap betwee …
Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the deposition of amyloid fibrils at the c …
Autonomic neuropathies.
Kaur D, Tiwana H, Stino A, Sandroni P. Kaur D, et al. Muscle Nerve. 2021 Jan;63(1):10-21. doi: 10.1002/mus.27048. Epub 2020 Sep 14. Muscle Nerve. 2021. PMID: 32926436 Free article. Review.
Of the chronic-onset forms, diabetes is the most widespread and disabling, with autonomic impairment portending increased mortality and cardiac wall remodeling risk. Acquired light chain (AL) and transthyretin (TTR) amyloidosis represent two other key etiologies, with TTR …
Of the chronic-onset forms, diabetes is the most widespread and disabling, with autonomic impairment portending increased mortality and c …
Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review.
Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Ruberg FL, et al. J Am Coll Cardiol. 2019 Jun 11;73(22):2872-2891. doi: 10.1016/j.jacc.2019.04.003. J Am Coll Cardiol. 2019. PMID: 31171094 Free PMC article. Review.
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an under-recognized cause of heart failure (HF) in older adults, resulting from myocardial deposition of misfolded transthyretin (TTR) or pre-albumin. Characteristic patterns of echocardiography and cardiac magnetic …
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an under-recognized cause of heart failure (HF) in older adults, resulting from myo …
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.
Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C; ATTR-ACT Study Investigators. Maurer MS, et al. N Engl J Med. 2018 Sep 13;379(11):1007-1016. doi: 10.1056/NEJMoa1805689. Epub 2018 Aug 27. N Engl J Med. 2018. PMID: 30145929 Free article. Clinical Trial.
Cardiac Amyloidosis.
Gertz MA. Gertz MA. Heart Fail Clin. 2022 Jul;18(3):479-488. doi: 10.1016/j.hfc.2022.02.005. Heart Fail Clin. 2022. PMID: 35718420 Free PMC article. Review.
In cardiology, the 2 most common subunits accounting for well more than 90% of cardiac amyloidosis are either immunoglobulin light chain, amyloid light-chain (AL) amyloidosis, or transthyretin; transthyretin (TTR) amyloidosis. Although 70% of patients with systemic amyloid …
In cardiology, the 2 most common subunits accounting for well more than 90% of cardiac amyloidosis are either immunoglobulin light ch …
Systemic amyloidosis from A (AA) to T (ATTR): a review.
Muchtar E, Dispenzieri A, Magen H, Grogan M, Mauermann M, McPhail ED, Kurtin PJ, Leung N, Buadi FK, Dingli D, Kumar SK, Gertz MA. Muchtar E, et al. J Intern Med. 2021 Mar;289(3):268-292. doi: 10.1111/joim.13169. Epub 2020 Sep 14. J Intern Med. 2021. PMID: 32929754 Free article. Review.
Amyloidosis can be acquired or hereditary and can affect various organs, including the heart, kidneys, liver, nerves, gastrointestinal tract, lungs, muscles, skin and soft tissues. ...
Amyloidosis can be acquired or hereditary and can affect various organs, including the heart, kidneys, liver, nerves, gastrointestina …
When to Suspect a Diagnosis of Amyloidosis.
Vaxman I, Gertz M. Vaxman I, et al. Acta Haematol. 2020;143(4):304-311. doi: 10.1159/000506617. Epub 2020 Apr 27. Acta Haematol. 2020. PMID: 32340017 Review.
Amyloidosis is still underdiagnosed, even though treatments are now available and are effective in improving patient's survival and quality of life. Cardiac amyloidosis is the major determinant of survival, and the earlier it is detected the better the survival. ...
Amyloidosis is still underdiagnosed, even though treatments are now available and are effective in improving patient's survival and quality …
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.
Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AW, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN. Gillmore JD, et al. Circulation. 2016 Jun 14;133(24):2404-12. doi: 10.1161/CIRCULATIONAHA.116.021612. Epub 2016 Apr 22. Circulation. 2016. PMID: 27143678
BACKGROUND: Cardiac transthyretin (ATTR) amyloidosis is a progressive and fatal cardiomyopathy for which several promising therapies are in development. ...We propose noninvasive diagnostic criteria for cardiac ATTR amyloidosis that are applicable to the majority of …
BACKGROUND: Cardiac transthyretin (ATTR) amyloidosis is a progressive and fatal cardiomyopathy for which several promising therapies …
Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment.
Gertz MA. Gertz MA. Am J Hematol. 2024 Feb;99(2):309-324. doi: 10.1002/ajh.27177. Epub 2023 Dec 14. Am J Hematol. 2024. PMID: 38095141 Free article.
Clinical features depend on organs involved but can include heart failure with preserved ejection fraction, nephrotic syndrome, hepatic dysfunction, peripheral/autonomic neuropathy, and "atypical smoldering multiple myeloma or MGUS." ...
Clinical features depend on organs involved but can include heart failure with preserved ejection fraction, nephrotic syndrome, hepat …
Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy.
Coelho T, Marques W Jr, Dasgupta NR, Chao CC, Parman Y, França MC Jr, Guo YC, Wixner J, Ro LS, Calandra CR, Kowacs PA, Berk JL, Obici L, Barroso FA, Weiler M, Conceição I, Jung SW, Buchele G, Brambatti M, Chen J, Hughes SG, Schneider E, Viney NJ, Masri A, Gertz MR, Ando Y, Gillmore JD, Khella S, Dyck PJB, Waddington Cruz M; NEURO-TTRansform Investigators. Coelho T, et al. JAMA. 2023 Oct 17;330(15):1448-1458. doi: 10.1001/jama.2023.18688. JAMA. 2023. PMID: 37768671 Free PMC article.
Through week 66, there were 2 deaths in the eplontersen group consistent with known disease-related sequelae (cardiac arrhythmia; intracerebral hemorrhage); there were no deaths in the placebo group. ...
Through week 66, there were 2 deaths in the eplontersen group consistent with known disease-related sequelae (cardiac arrhythmia; int …
409 results